These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9143642)

  • 21. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of buspirone in withdrawal from opiates.
    Rose JS; Branchey M; Wallach L; Buydens-Branchey L
    Am J Addict; 2003; 12(3):253-9. PubMed ID: 12851021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Yohimbine in the treatment of erectile dysfunction].
    Pushkar' DIu; Segal AS; Bagaev AG; Nosovitskiĭ PB
    Urologiia; 2002; (6):34-7. PubMed ID: 12577576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study.
    Kunelius P; Häkkinen J; Lukkarinen O
    Urology; 1997 Mar; 49(3):441-4. PubMed ID: 9123711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects.
    Kernohan AF; McIntyre M; Hughes DM; Tam SW; Worcel M; Reid JL
    Br J Clin Pharmacol; 2005 Jan; 59(1):85-93. PubMed ID: 15606445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):137-141. PubMed ID: 30133420
    [No Abstract]   [Full Text] [Related]  

  • 27. Expanded table: Some drugs for management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):e144-e146. PubMed ID: 30133422
    [No Abstract]   [Full Text] [Related]  

  • 28. The influence of chronic treatment with clonidine, yohimbine and idazoxan on morphine withdrawal.
    El-Kadi AO; Sharif SI
    Psychopharmacology (Berl); 1997 Jul; 132(1):67-73. PubMed ID: 9272761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: evidence for noradrenergic hyperactivity.
    Charney DS; Redmond DE; Galloway MP; Kleber HD; Heninger GR; Murberg M; Roth RH
    Life Sci; 1984 Sep; 35(12):1263-72. PubMed ID: 6482651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal.
    Bearn J; Gossop M; Strang J
    Drug Alcohol Depend; 1996 Dec; 43(1-2):87-91. PubMed ID: 8957147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lithium inhibits the development of physical dependence to clonidine in mice.
    Dehpour AR; Sadr SS; Azizi MR; Namiranian K; Farahani M; Javidan AN
    Pharmacol Toxicol; 2002 Feb; 90(2):89-93. PubMed ID: 12071431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance.
    Stine SM; Kosten TR
    Am J Drug Alcohol Abuse; 1994 Nov; 20(4):445-58. PubMed ID: 7832179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X; Farre M; Cami J
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serendipitous rapid detoxification from opiates: the importance of time-dependent processes.
    Mannelli P; De Risio S; Pozzi G; Janiri L; De Giacomo M
    Addiction; 1999 Apr; 94(4):589-91. PubMed ID: 10605854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reliability of sequential naloxone challenge tests.
    Rosen MI; McMahon TJ; Margolin A; Gill TS; Woods SW; Pearsall HR; Kreek MJ; Kosten TR
    Am J Drug Alcohol Abuse; 1995 Nov; 21(4):453-67. PubMed ID: 8561097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opiate withdrawal.
    Farrell M
    Addiction; 1994 Nov; 89(11):1471-5. PubMed ID: 7841858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of G protein-coupled receptor kinase 2 in brains of opiate-treated rats and human opiate addicts.
    Ozaita A; Escribá PV; Ventayol P; Murga C; Mayor F; García-Sevilla JA
    J Neurochem; 1998 Mar; 70(3):1249-57. PubMed ID: 9489748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Naltrexone-assisted rapid methadone discontinuation: a pilot study.
    Camarasa X; Khazaal Y; Besson J; Zullino DF
    Eur Addict Res; 2007; 13(1):20-4. PubMed ID: 17172775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
    Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
    Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yohimbine co-treatment during chronic morphine administration attenuates naloxone-precipitated withdrawal without diminishing tail-flick analgesia in rats.
    Taylor JR; Lewis VO; Elsworth JD; Pivirotto P; Roth RH; Redmond DE
    Psychopharmacology (Berl); 1991; 103(3):407-14. PubMed ID: 2057541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.